Back to Search
Start Over
Direct oral anticoagulants: a treatment option in oncological patients
- Source :
- memo - Magazine of European Medical Oncology. 12:115-118
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Venous thrombosis and pulmonary embolism are common complications in patients with active cancer. For many years low molecular weight heparins (LMWH) have been the preferred treatment option for cancer patients, because of their superiority over vitamin K antagonists, which bear high risk of interaction and unsatisfactory anticoagulation. With the introduction of direct oral anticoagulants (DOAC) a second oral treatment option appeared. However, recommendations for the use of DOACs in the treatment of cancer-associated venous thromboembolic events were only given recently. DOAC possess a different side effect profile regarding drug/drug interactions. Recent publications revealed a slightly increased risk for non major bleedings compared to LMWH, and caution is advised when used in patients with gastrointestinal tract malignancies, especially upper gastro-intestinal tract malignancies. This review depicts actual considerations for anticoagulation in cancer patients to provide a rational for clinicians before treatment initiation.
- Subjects :
- Drug
Gastrointestinal tract
Oral treatment
medicine.medical_specialty
Side effect
business.industry
media_common.quotation_subject
Cancer
Treatment options
Hematology
medicine.disease
Pulmonary embolism
03 medical and health sciences
Venous thrombosis
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Internal medicine
medicine
business
030215 immunology
media_common
Subjects
Details
- ISSN :
- 18655076 and 18655041
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- memo - Magazine of European Medical Oncology
- Accession number :
- edsair.doi...........ff7f48b69ee8ea066d2a5291b0d38438